WO2009081957A1 - Acat 2 阻害活性を有するピリピロペン誘導体 - Google Patents
Acat 2 阻害活性を有するピリピロペン誘導体 Download PDFInfo
- Publication number
- WO2009081957A1 WO2009081957A1 PCT/JP2008/073501 JP2008073501W WO2009081957A1 WO 2009081957 A1 WO2009081957 A1 WO 2009081957A1 JP 2008073501 W JP2008073501 W JP 2008073501W WO 2009081957 A1 WO2009081957 A1 WO 2009081957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- acyloxy
- mhz
- fab
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract description 19
- ROPBDLZCVLFSRF-SXGRAWJWSA-N chembl328676 Chemical compound C([C@@]1(C)C2C[C@@H]([C@]3(OC4=C(C(OC(=C4)C=4C=NC=CC=4)=O)[C@H](O)C3[C@@]2(C)CC[C@@H]1O1)C)OC(=O)C(N)CCC)OC21CCCCC2 ROPBDLZCVLFSRF-SXGRAWJWSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000012453 solvate Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- -1 2-hydroxylacetoxy group Chemical group 0.000 claims description 225
- 125000004423 acyloxy group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 12
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- VGLBAUNQTSZLNV-UHFFFAOYSA-N (4-cyanophenyl) hydrogen carbonate Chemical group OC(=O)OC1=CC=C(C#N)C=C1 VGLBAUNQTSZLNV-UHFFFAOYSA-N 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 6
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- QIIPQYDSKRYMFG-UHFFFAOYSA-N phenyl hydrogen carbonate Chemical group OC(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-N 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- ISZJQQWIYSBXLV-UHFFFAOYSA-N (4-chlorophenyl) hydrogen carbonate Chemical group OC(=O)OC1=CC=C(Cl)C=C1 ISZJQQWIYSBXLV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 229910052710 silicon Chemical group 0.000 claims description 2
- 239000010703 silicon Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 14
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 7
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract description 5
- 208000032928 Dyslipidaemia Diseases 0.000 abstract description 4
- 101000642613 Homo sapiens Sterol O-acyltransferase 2 Proteins 0.000 abstract description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 4
- 230000010534 mechanism of action Effects 0.000 abstract description 4
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 2
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 102100028704 Acetyl-CoA acetyltransferase, cytosolic Human genes 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
- 239000007787 solid Substances 0.000 description 88
- 238000003786 synthesis reaction Methods 0.000 description 82
- 230000015572 biosynthetic process Effects 0.000 description 77
- 239000011734 sodium Substances 0.000 description 69
- 239000000243 solution Substances 0.000 description 64
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 30
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 20
- 230000007935 neutral effect Effects 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 239000012300 argon atmosphere Substances 0.000 description 19
- 238000001914 filtration Methods 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- PMMQOFWSZRQWEV-RVTXXDJVSA-N pyripyropene A Chemical class O([C@]1(C)[C@@H](OC(C)=O)C[C@@H]2[C@]([C@H]1[C@@H](O)C=1C(=O)O3)(C)CC[C@@H]([C@@]2(C)COC(=O)C)OC(C)=O)C=1C=C3C1=CC=CN=C1 PMMQOFWSZRQWEV-RVTXXDJVSA-N 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 5
- 101150065749 Churc1 gene Proteins 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229930188995 pyripyropene Natural products 0.000 description 4
- PMMQOFWSZRQWEV-UHFFFAOYSA-N pyripyropene A Natural products CC(=O)OCC1(C)C(OC(C)=O)CCC(C2C(O)C=3C(=O)O4)(C)C1CC(OC(C)=O)C2(C)OC=3C=C4C1=CC=CN=C1 PMMQOFWSZRQWEV-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100036673 Sterol O-acyltransferase 2 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 101150070147 arx-2 gene Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- YBLWHPAOSHAFTR-UHFFFAOYSA-N 2-(1-phenylpyrrol-2-yl)-3-pyrrol-2-ylidenepyrrole Chemical group C1(=CC=CC=C1)N1C(=CC=C1)C1=NC=CC1=C1N=CC=C1 YBLWHPAOSHAFTR-UHFFFAOYSA-N 0.000 description 1
- MPQNQGQOCILART-UHFFFAOYSA-N 2-(1-trityltetrazol-5-yl)acetic acid Chemical compound OC(=O)CC1=NN=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 MPQNQGQOCILART-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JUNAPQMUUHSYOV-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)acetic acid Chemical compound OC(=O)CC=1N=NNN=1 JUNAPQMUUHSYOV-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- TZDMCKHDYUDRMB-UHFFFAOYSA-N 2-(5-methyl-2,4-dioxopyrimidin-1-yl)acetic acid Chemical compound CC1=CN(CC(O)=O)C(=O)NC1=O TZDMCKHDYUDRMB-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DTNSDCJFTHMDAK-UHFFFAOYSA-N 2-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C#N DTNSDCJFTHMDAK-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- ZSSFHNJNSFUUMD-UHFFFAOYSA-N 3-azapentacyclo[9.6.2.02,6.07,19.014,18]nonadeca-1(17),2(6),4,7,9,11(19),12,14(18),15-nonaene Chemical compound C1=CC=C2C=CC3=CC=CC4=C5C(=C1C2=C34)C=CN5 ZSSFHNJNSFUUMD-UHFFFAOYSA-N 0.000 description 1
- XHQZJYCNDZAGLW-UHFFFAOYSA-N 3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1 XHQZJYCNDZAGLW-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERHUKIBUIBJHN-UHFFFAOYSA-N C1(=CC=CC=C1)[SiH](OC(C(=O)O)CCC)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)[SiH](OC(C(=O)O)CCC)C1=CC=CC=C1 FERHUKIBUIBJHN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 229910013594 LiOAc Inorganic materials 0.000 description 1
- 240000005265 Lupinus mutabilis Species 0.000 description 1
- 235000008755 Lupinus mutabilis Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100310622 Mus musculus Soga1 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019095 Sechium edule Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical group COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the present invention relates to a pyripyropene A derivative having an excellent cholesterol acyltransferase isozyme (hereinafter abbreviated as ACAT) 2 inhibitory activity, and more particularly, to a 7-position acyl derivative or a 1, 11-position cyclic acetal ⁇ 7-position acyl derivative.
- ACAT cholesterol acyltransferase isozyme
- HMG-CoA hydroxy-3-methyl glutaryr coenzyme A
- HMG-CoA reductase inhibitors which are prophylactic and therapeutic agents for arteriosclerosis, do not sufficiently suppress cardiovascular diseases include the following.
- the onset mechanism of arteriosclerosis is complex, and genetic 'diagnosis tailored to each patient's condition' treatment is necessary because various factors such as diabetes and drugs often occur. Therefore, there is an urgent need to develop a drug with a new mechanism of action that can be expected to suppress the onset of coronary arteries and to regress coronary artery lesions, which has a different mechanism of action from statin drugs.
- statin drugs there is little progress in the development of drugs that can replace statins.
- ACAT is an enzyme that introduces an acyl group into cholesterol, and is a drug target that is expected to develop treatment for statin-resistant arteriosclerosis and tailor-made medicine according to individual pathologies. This enzyme has been attracting attention as an important target molecule for arteriosclerosis prevention and treatment for many years. Numerous synthetic ACAT inhibitors have been developed, but no side effects or sufficient effects have been observed, and they have not yet been put into clinical use (Meuwese et al., Curr. Op in. Lipidol. 17, 426 -431 pages, 2006).
- ACAT has two types of isozymes, ACAT 1 (expressed in many cell tissues) and ACAT 2 (specific expression in the small intestine and liver). Differences become apparent, and the importance of clarifying the selectivity of drug discovery targeting ACAT has been recognized again (Chang et al., Acta. Biochim. Biophys. Sin. 38 ⁇ , 15 ⁇ 156) , 2006).
- ACAT 1 selective inhibition eg Wu-V-23
- ACAT 1 and ACAT 2 lysozyme inhibition eg Abashimibe or Pakimimibe.
- An object of the present invention is to provide a drug effective for the prevention or treatment of arteriosclerosis having a mechanism of action different from that of statin drugs.
- the present inventors have found that a novel pyripyropene A derivative has ACAT 2 selective and high inhibitory activity, which has attracted attention as a target for the prevention and treatment of arteriosclerosis. It was a perfect match. That is, the present invention relates to the following general formula (I) described in claim 1.
- R, R ', R are a lower acyloxy group, a substituted lower acyloxy group, an aromatic acyloxy group, a substituted arylacyloxy group, a arylacyloxy group, a heteroaryl acyloxy group, a substituted helicyloxy group, Terarylsilyloxy group, lower alkoxy group, substituted lower alkoxy group, strong rubamoyl group, lower alkylaminoacyloxy group, substituted alkylaminoacyloxy group, lower alkylsulfonyl group, substituted lower alkylsulfonyl group, Aromatic sulfonyl group, lower alkyl group, substituted lower alkyl group, aromatic sulfanyl group, substituted aromatic sulfanyl group, tetrazyl group, substituted tetrazoyl group, triazol group, substituted triazol group, azide group, Amino group, cyan
- R, R ′ and R ′′ may be the same or different, and each represents a cetoxy group, 2-aminoacetoxy group, 2-hydroxylacetoxy group, 2-acetamide group, n-propionyloxy group, ⁇ propionyloxy group, n-butylyloxy group, i-butyloxy group, s-butyryloxy group, t-butyryloxy group, n-valeryloxy group, cyclopropanecarbox Xyl group, cyclobutane carboxyl group, cyclohexane carboxyl group, 1-adamanyl carboxyl group, benzoyloxy group, 2-methoxybenzoyloxy group, 3-methoxybenzoyloxy group, 4-methoxybenzo group Yloxy group, 2-iodobenzoyloxy group, 3-iodobenzoyloxy group, 4-iodobenzoyloxy group, 2-methylbenzoyloxy group, 3-methylbenzo
- R and FT ′ are a lower acyloxy group, a substituted lower acyloxy group, an aromatic acyloxy group, a substituted arylacyloxy group, an arylacyloxy group, a heteroarylacyloxy group, a substituted heteroarylacyloxy group, Lower alkoxyacyloxy group, substituted lower alkoxyacyloxy group, strong rubamoyl group, lower alkylaminoacyloxy group, substituted alkylaminoacyloxy group, lower alkylsulfonyl group, substituted lower alkylsulfonyl group, aromatic sulfonyl Group, lower alkyl group, substituted lower alkyl group, aromatic sulfanyl group, substituted aromatic sulfanyl group, substituted tetrazyl group, triazol group, substituted arylazoyl group, azide group, amino group, cyano group A group, a substituted amino group, R ′ and R ′′
- R and R ′ ′ ′ are respectively acetoxy group, 2-aminoacetoxy group, 2-hydroxylucacetoxy group, 2-acetamido group, n-propionyloxy group, i-propionyloxy group.
- R, R ', R are lower acyloxy groups, substituted lower acyloxy groups, aromatic acyloxy groups, substituted arylacyloxy groups, arylyloxy groups, heteroaryl acyloxy groups, Teloaryl acyloxy group, lower alkoxy acyloxy group, substituted lower alkoxy acyloxy group, strong rubamoyl group, lower alkylamino acyloxy group, substituted alkyl amino acyloxy group, lower alkyl sulfonyl group, substituted Lower alkylsulfonyl group, aromatic sulfonyl group, lower alkyl group, substituted lower alkyl group, aromatic sulfanyl group, substituted aromatic sulfanyl group, triazol group, substituted triazol group, azide group, amino Group, cyano group, substituted amino group, halogen group) Compound, or pharmaceutical and to permit -. Salt, a Solvent solvates or hydrates.
- R, R ′ and R ′′ may be the same or different, Acetoxy, 2-aminoacetoxy, 2-hydroxylacetoxy, 2-acetamide, n-propionyl Xyl group, i-propionyl-oxy group, n-butyryloxy group, i-butyl-oxy group, s-butyryloxy group, t-butyryloxy group, n-valeryloxy group, cyclopropanecarboxyl group, cyclobutanecarboxyl group, cyclohexane Xanthcarboxyl group, 1-adamantanecarboxyl group, Benzyloxy group, 2-Methoxybenzoyloxy group, 3-Methoxybenzoyloxy group, 4-Methoxybenzoyloxy group, 2-Yodo Benzyloxy group, 3-iod
- the present invention is an ACAT 2 inhibitor comprising as an active ingredient a compound selected from the group of compounds described in any one of claims 1 to 6, a pharmaceutically acceptable salt, a solvate or a hydrate. is there.
- the present invention also relates to a preparation for inhibiting ACAT 2 comprising as an active ingredient a compound selected from the group of compounds described in any of claims 1 to 6, a pharmaceutically acceptable salt, a solvate or a hydrate. is there.
- lower alkyl group “lower alkoxy group”, and “lower acyloxy group” as a group or a part of the group are those in which the group is a straight chain or branched chain having 1 to 16 carbon atoms, preferably Means an alkyl group, an alkoxy group, or an acyloxy group of 1-4.
- lower alkyl as a group or part of a group include methyl, ethyl, n-propyl, isopropyl, n-butyl, i-butyl, S-butyl, t-butyl, n-pentyl, ne Opentyl, i-pentyl, t-pentyl, n-hexyl, i-hexyl and the like.
- lower alkoxy as a group or part of a group include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, S-butoxy, t-butoxy, and n-pentyloxy.
- Neopentyloxy, i-pentyloxy, t-pentyloxy, n-hexyloxy, and hexyl-resistant xyl examples include: acetoxy, propionyloxy, i-propionyloxy, n-butyryloxy, i-butyryloxy, s-butyryloxy, Examples include t-butyryloxy, n-valeryloxy, neovaleryloxy, i-valeryloxy, t-valeryloxy, n-capryloxy, i-force prolyloxy and the like.
- halogen atom refers to each atom of fluorine, chlorine, bromine, and iodine.
- cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- aryl group as a group or part of a group means a phenyl group or a naphthyl group.
- heteroaryl group as a group or part of a group is the same or different and has one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- a 6-membered aromatic heterocyclic ring or a polycyclic heterocyclic aromatic compound Preferably, furan, pyrrole, imidazole, thiazole, triazole, tetrazol, thiadia oral, pyridine, pyridazine, pyrimidine, Indole, thianaphthene, etc.
- the pharmaceutical composition of the present invention can be formulated by methods known to those skilled in the art.
- the compound of the present invention may be converted into a pharmaceutically acceptable carrier or medium, such as sterile water or physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, It can be formulated by mixing in a unit dosage form as required by generally accepted pharmaceutical practice, in appropriate combination with the form, vehicle, preservative, binder, etc.
- tablets, pills, dragees, capsules, liquids, gels by mixing the compounds of the invention or their salts with pharmaceutically acceptable carriers well known in the art. It can be formulated as a syrup, slurry, suspension, etc.
- the carrier those conventionally known in the technical field can be widely used. For example, lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, key acid, etc.
- Excipients water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylzelulose, potassium phosphate, polypyrrole pyrrolidone and other binders, dried starch, sodium alginate, Agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid, monoglyceride acid, starch, lactose, etc .; sucrose, steak cacao butter, water Collapse of additive oil Absorption promoters such as quaternary ammonium salts and sodium lauryl sulfate; humectants such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite and colloidal gay acid; purified talc, Lubricants such as stearate, boric acid powder, and polyethylene glycol can
- the compounds of the present invention or salts thereof can be formulated according to conventional pharmaceutical practice using pharmaceutically acceptable vehicles well known in the art.
- water-soluble vehicles for injection include isotonic solutions containing physiological saline, glucose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride.
- Solubilizers such as alcohols, specifically alcohol, polyalcohols such as propylene glycol, polyethylene glycol A nonionic surfactant such as polysorbate 80 (TM) or HC0-50 may be used in combination.
- Oily vehicles include sesame oil and soybean oil, which may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizer.
- a buffering agent such as phosphate buffer, sodium acetate buffer, a soothing agent such as hydrochloric acid pro-in, a stabilizer such as benzyl alcohol, methanol or an antioxidant may be added.
- the prepared injection is usually filled in a suitable ampoule.
- Suitable administration routes for the pharmaceutical composition of the present invention include, but are not limited to, oral, rectal, transmucosal, or enteral administration, or intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous Intravitreal, intraperitoneal, intranasal, or intraocular injection.
- the administration route can be appropriately selected in consideration of the age and medical condition of the patient, other drugs used in combination.
- the dosage of the pharmaceutical composition of the present invention can be selected in the range of 0.001 mg to 10 mg / kg body weight per administration. Alternatively, the dose can be selected within the range of 0.1 to 100 mg per administration, but is not necessarily limited to these values.
- the dose and method of administration can be appropriately selected by the doctor in charge taking into account the patient's weight, age, symptoms, other drugs used in combination, and the like. Effects of the invention ...
- the pyripyropene derivatives represented by the formulas (I), (11) and (I I I) of the present invention and pharmacologically acceptable salts thereof have excellent ACAT 2 inhibitory activity.
- a pharmaceutical composition comprising as an active ingredient the compound of the present invention, a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or other pharmacologically acceptable derivative thereof is a prophylactic agent for arteriosclerotic diseases. Gu is useful as a therapeutic agent. Best mode for carrying out the invention
- Rl and R2 are acetoxy group and R is an acyloxy group, they can be produced by the following scheme.
- the compound of the formula (a) in the above scheme can be synthesized by a conventional method (for example, Obata et al., “Antibiot. 49”, pages 1133-1148, 1996).
- the conversion from (a) to (b) can be done by the following method. That is, 1 equivalent or excess amount of the corresponding carboxylic acid R * C0 2 H with respect to (a) and 1 equivalent or excess amount of condensing agent (preferably, .1-ethyl-3- (3-dimethyl In the presence of 0.5 equivalents or an excess of an organic base (preferably dimethylaminopyridine), dichloromethane, dimethylformamide, tetrahydrodolfuran, (B) can be obtained by subjecting to a reaction after 30 minutes to 2 days at room temperature in acetonidol or the like and a mixed solvent thereof and then subjecting it to a usual post-treatment.
- 1 equivalent or excess amount of the corresponding carboxylic acid R * C0 2 H with respect to (a) and 1 equivalent or excess amount of condensing agent preferably, .1-ethyl-3- (3-dimethyl
- an organic base preferably dimethylaminopyridine
- the conversion from (c) to (d) can be performed by the following method. That is, 1 equivalent or excess of the corresponding carboxylic acid R * C0 2 H with respect to (c), and 1 equivalent or excess of condensing agent (preferably cetyl-3- (3-dimethylamino) Propyl), carbodiimide hydrochloride or dicyclohexyl carbodiimide), and 0.5 equivalent or excess of an organic salt (preferably dimethylaminopyridine) in the presence of dichloromethane, dimethylformamide, tetrahydrofuran, acetonidyl, etc. (D) can be obtained by reacting in a mixed solvent at room temperature for 30 minutes to 2 days and then subjecting the mixture to ordinary post-treatment.
- condensing agent preferably cetyl-3- (3-dimethylamino) Propyl
- an organic salt preferably dimethylaminopyridine
- the obtained foam was dissolved in tBuOH / H 2 0 1: 1 solution (10 mL), NaC10 2 (271 mg, 3.0 0 ⁇ ol), NaHP0 4 -2H 2 0 (468 mg, 3.00 mmol), 2-methyl-2-butene (424 L, 4.00 mmol) was added, and the mixture was stirred at room temperature for 48 hours.
- EtOAc was added to the reaction solution for dilution, and the organic layer was washed three times with water and dried over anhydrous sodium sulfate.
- OKbr s, 1H, OH-13) , 2.23-1.25 (m, 8H, H-2, 3, 5, 8, 9), 2.13 (s, 3H, Ac), 2.05 (s, 3H, Ac), 1.84 (s, 3H, Me), 1.50 (s, 3H, Me), 0.91 (s, 3H, Me).
- EDCI (16 mg, 82.5 ⁇ raol) in a CH 2 C1 2 (0.5 mL) solution of I (15 mg, 27.5 w mol) under argon atmosphere.
- Diphenylsiloxypentanoic acid 22 mg, 61.8 imol was added, and the mixture was stirred at room temperature for 4.5 hours.
- EtOAc was added to the reaction solution for dilution, and the organic layer was washed with IN HC1 aqueous solution and water, and dried over anhydrous sodium sulfate.
- Awakening R (CDC1 3 , 150 MHz) ⁇ 164.98, 164.01, 162.28, 159.78, 157.31, 151.53, 146.8 3, 142.05, 138.27, 134.22, 132.95, 132.09, 129.02, 128.36, 127.17, 126.29, 123.62, 120. 20 , 119.27, 112.15, 102.89, 102.81, 99.48, 85.68, 83.70, 78.32, 78.15, 60.25, 55.93, 54. 71, 48.88, 38.38, 37.11, 36.53, 29.69, 25.09, 23.15, 18.22, 16.67, 13.26.
- Inhibition rate 100— [(Radioactivity when test compound is added) I (Background)] /
- the concentration that inhibits this enzyme activity by 50% (1) was calculated. Furthermore, the specific activity for pyripyropene A was calculated by the following formula.
- Example 23 The derivative of Example 23 (PRD024) showed a specific activity 100 times or more that of pyripyropene A with respect to ACAT2.
- Inhibitory activity concentration that inhibits ACAT2 by 50%
- the ACAT 2 inhibitory activity test is not limited to the above method.
- microsomes prepared from the small intestine or liver of animals such as rats and monkeys may be used as the ACAT 2 enzyme. It is also possible to use cultured cells (Caco 2 intestinal cells, primary hepatocytes, the He P G 2 hepatocytes, etc.) microsomes were prepared or ACAT 2 from cultured cells is highly expressed as ACAT enzyme source.
- a 10-week-old apolipoprotein E-deficient mouse male, purchased from Jackson Laboratories Inc.
- a standard high-fat diet D12079B, research diet
- 100 U 1 was collected from the tail vein of these animals, and the total cholesterol concentration in plasma was measured using a commercially available kit (Detamina TC55 5, manufactured by Kyowa Medex). did. Based on this concentration, mice were categorized so that there was no difference between the mice receiving each test drug.
- Example 1 Pyridopopen A and the derivatives of Example 1 (PRD017), Example 63 (PRD041) and Example 86 (PRD059) were dissolved in 0.51 (w / v) carboxymethylcellulose in physiological saline, Piropen A is 10 mg / kg and 50 mg / kg.
- PRD041 and PRD056 are administered to mice at 2.5 ml / kg to a concentration of 1 mg / kg, 10 mg / kg and 50 mg / kg. did. The drug was administered orally once daily every day at the start of the artificial light cycle.
- Table 2 shows the results obtained for the percentage increase in total plasma cholesterol.
- the total plasma cholesterol level increased to 212.2%
- the value was 177.3% (10 mg / kg) and 174.0% (50 mg / kg).
- the values decreased to 161.6% (lmg / kg), 149.7% (10 mg / kg), and 132.5% (50 mg / kg).
- the value decreased to 102.4% (lmg / kg), 88.2% (10 rag / kg), and 101.1% (50 mg / kg).
- the compound of the present invention has excellent ACAT 2 inhibitory activity and is caused by obesity, obesity, hyperlipidemia, hypercholesterolemia, dyslipidemia, arteriosclerosis, or obesity It is useful as a therapeutic or prophylactic agent for hyperlipidemia, hypercholesterolemia, dyslipidemia, arteriosclerosis, or hypertension.
- the pyripylobene derivative of the present invention and its pharmacologically acceptable salt have excellent ACAT 2 inhibitory activity.
- a pharmaceutical composition containing the compound of the present invention, a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester or other pharmacologically acceptable derivative thereof as an active ingredient is a preventive agent for arteriosclerotic disease or It is useful as a therapeutic agent (therapeutic agent). Therefore, the compound according to the present invention can be widely used for the prevention and treatment of arteriosclerosis in animals including humans.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/810,545 US8519128B2 (en) | 2007-12-25 | 2008-12-17 | Pyripyropene derivatives having an ACAT2-inhibiting activity |
JP2009547119A JP5479110B2 (ja) | 2007-12-25 | 2008-12-17 | Acat2阻害活性を有するピリピロペン誘導体 |
EP08864334.1A EP2228376B1 (en) | 2007-12-25 | 2008-12-17 | Pyripyropene derivative having acat2-inhibiting activity |
CN2008801274459A CN101965352A (zh) | 2007-12-25 | 2008-12-17 | 具有acat2抑制活性的匹立匹老芬衍生物 |
BRPI0821921-4A BRPI0821921A2 (pt) | 2007-12-25 | 2008-12-17 | Derivados de piripiropeno tendo uma atividade inibidora da acat2 |
CA2710791A CA2710791A1 (en) | 2007-12-25 | 2008-12-17 | Pyripyropene derivatives having an acat2-inhibiting activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007331444 | 2007-12-25 | ||
JP2007-331444 | 2007-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009081957A1 true WO2009081957A1 (ja) | 2009-07-02 |
Family
ID=40801257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/073501 WO2009081957A1 (ja) | 2007-12-25 | 2008-12-17 | Acat 2 阻害活性を有するピリピロペン誘導体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8519128B2 (ja) |
EP (1) | EP2228376B1 (ja) |
JP (1) | JP5479110B2 (ja) |
CN (1) | CN101965352A (ja) |
BR (1) | BRPI0821921A2 (ja) |
CA (1) | CA2710791A1 (ja) |
WO (1) | WO2009081957A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150739A1 (ja) * | 2009-06-23 | 2010-12-29 | 学校法人北里研究所 | Acat2阻害活性を示す水酸基含有ピリピロペン誘導体 |
WO2011122468A1 (ja) | 2010-03-31 | 2011-10-06 | 学校法人北里研究所 | Acat2阻害活性を示す代謝酵素に安定なピリピロペン誘導体 |
WO2011148886A1 (ja) | 2010-05-24 | 2011-12-01 | Meiji Seikaファルマ株式会社 | 有害生物防除剤 |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2014144922A (ja) * | 2013-01-28 | 2014-08-14 | Kitasato Institute | Acat2阻害活性を示すピリピロペンa構造簡略型誘導体 |
WO2015198966A1 (ja) * | 2014-06-24 | 2015-12-30 | 学校法人北里研究所 | コレステロールアシル転移酵素アイソザイム2(acat2)阻害活性を有する新規医薬化合物 |
US9856478B2 (en) | 2013-10-30 | 2018-01-02 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
WO2020063663A1 (zh) * | 2018-09-27 | 2020-04-02 | 中国科学院上海药物研究所 | 一类三环类似物、其制备方法和用途 |
JPWO2021153570A1 (ja) * | 2020-01-27 | 2021-08-05 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536922B (zh) * | 2012-07-13 | 2017-05-03 | 中国科学院上海生命科学研究院 | 酰基辅酶a:胆固醇酰基转移酶‑2抑制剂在抑制肝癌生长中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08259569A (ja) * | 1995-03-27 | 1996-10-08 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269065A (ja) * | 1995-04-03 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
WO2006129714A1 (ja) * | 2005-06-01 | 2006-12-07 | Meiji Seika Kaisha, Ltd. | 害虫防除剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3233476B2 (ja) * | 1992-10-22 | 2001-11-26 | 社団法人北里研究所 | Fo−1289物質およびその製造法 |
DE102004036689A1 (de) | 2004-07-28 | 2006-03-23 | Henkel Kgaa | Rückstandsarmer Deodorant- oder Antitranspirant-Stift auf Basis einer Öl-in-Wasser-Dispersion |
-
2008
- 2008-12-17 CA CA2710791A patent/CA2710791A1/en not_active Abandoned
- 2008-12-17 CN CN2008801274459A patent/CN101965352A/zh active Pending
- 2008-12-17 JP JP2009547119A patent/JP5479110B2/ja active Active
- 2008-12-17 EP EP08864334.1A patent/EP2228376B1/en active Active
- 2008-12-17 BR BRPI0821921-4A patent/BRPI0821921A2/pt not_active IP Right Cessation
- 2008-12-17 US US12/810,545 patent/US8519128B2/en active Active
- 2008-12-17 WO PCT/JP2008/073501 patent/WO2009081957A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08259569A (ja) * | 1995-03-27 | 1996-10-08 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269065A (ja) * | 1995-04-03 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
WO2006129714A1 (ja) * | 2005-06-01 | 2006-12-07 | Meiji Seika Kaisha, Ltd. | 害虫防除剤 |
Non-Patent Citations (23)
Title |
---|
BELL ET AL., ARTERIOSCLER. THROMB. VASC. BIOL., vol. 27, 2007, pages 1396 - 1402 |
BLIGH; DYER, CAN. J. BIOCHEM. PHYSIOL., vol. 37, 1959, pages 911 - 917 |
CHANG ET AL., ACTA. BIOCHIM. BIOPHYS. SIN., vol. 38, 2006, pages 151 - 156 |
CHO, K. ET AL.: "Mass-production of human ACAT-1 and ACAT-2 to screen isoform-specific inhibitor: a different substrate specificity and inhibitory regulation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 309, no. 4, 2003, pages 864 - 872, XP004455821 * |
FARESE, ARTERIOSCLER. THROMB. VASC. BIOL., vol. 26, 2006, pages 1684 - 1686 |
LADA ET AL., J. LIPID RES., vol. 45, 2004, pages 378 - 386 |
LADA, A.T. ET AL.: "Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell- based fluorescence assay: Individual ACAT uniqueness", JOURNAL OF LIPID RESEARCH, vol. 45, no. 2, 2004, pages 378 - 386, XP008137572 * |
MEUWESE ET AL., CURR. OPIN. LIPIDOL., vol. 17, 2006, pages 426 - 431 |
OBATA ET AL., J. ANTIBIOT., vol. 49, 1996, pages 1133 - 1148 |
OBATA ET AL., J. ANTIBIOT., vol. 49, 1996, pages 1149 - 1156 |
OBATA, R. ET AL.: "Chemical modification and structure-activity relationships of pyripyropenes. 1. Modification at the four hydroxyl groups", JOURNAL OF ANTIBIOTICS, vol. 49, no. 11, 1996, pages 1133 - 1148, XP003002774 * |
OBATA, R. ET AL.: "Chemical modification and structure-activity relationships of pyripyropenes. 2. 1, 11-Cyclic analogs", JOURNAL OF ANTIBIOTICS, vol. 49, no. 11, 1996, pages 1149 - 1156, XP008130150 * |
OBATA, R. ET AL.: "Chemical modification and structure-activity relationships of pyripyropenes. 3. Synthetic conversion of pyridine-pyrone moiety", JOURNAL OF ANTIBIOTICS, vol. 50, no. 3, 1997, pages 229 - 236, XP008137574 * |
OBATA, R. ET AL.: "Chemical modification and structure-activity relationships of pyripyropenes; potent, bioavailable inhibitor of acyl-CoA: cholesterol O-acyltransferase (ACAT)", BIOORGANIC, XP004135214 * |
OBATA, R. ET AL.: "Structure-activity relationships of pyripyropenes fungal acyl-CoA: cholesterol acyltransferase inhibitors", JOURNAL OF ANTIBIOTICS, vol. 48, no. 7, 1995, pages 749 - 750, XP008137618 * |
OBATA, R. ET AL.: "Structure-activity relationships study of pyripyropenes: reversal of cancer cell multidrug resistance", JOURNAL OF ANTIBIOTICS, vol. 53, no. 4, 2000, pages 422 - 425, XP008137617 * |
OHSHIRO, T. ET AL.: "Selectivity of microbial acyl -CoA: cholesterol acyltransferase inhibitors toward isozymes", JOURNAL OF ANTIBIOTICS, vol. 60, no. 1, 2007, pages 43 - 51, XP008137566 * |
TAMIO TERAMOTO; NAKAYAMA SHOTEN, LIFESTYLE RELATED DISEASE, 2001, pages 119 |
THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 126, no. 3, 6 March 2006 (2006-03-06), pages 21 * |
THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 127, no. 4, 5 March 2007 (2007-03-05), pages 6 * |
TOMODA ET AL., J. ANTIBIOT., vol. 47, 1994, pages 148 - 153 |
TOMODA, H. ET AL.: "Pyripyropenes, novel ACAT inhibitors produced by Aspergillus fumigatus IV. Structure elucidation of pyripyropenes M to R", JOURNAL OF ANTIBIOTICS, vol. 49, no. 3, 1996, pages 292 - 298, XP008137616 * |
UELMEN ET AL., J. BIOL. CHEM, vol. 270, 1995, pages 26192 - 26201 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150739A1 (ja) * | 2009-06-23 | 2010-12-29 | 学校法人北里研究所 | Acat2阻害活性を示す水酸基含有ピリピロペン誘導体 |
WO2011122468A1 (ja) | 2010-03-31 | 2011-10-06 | 学校法人北里研究所 | Acat2阻害活性を示す代謝酵素に安定なピリピロペン誘導体 |
CN102947313A (zh) * | 2010-03-31 | 2013-02-27 | 学校法人北里研究所 | 对表现ACAT2抑制活性的代谢酶稳定的啶南平(Pyripyropene)衍生物 |
JP5592482B2 (ja) * | 2010-03-31 | 2014-09-17 | 学校法人北里研究所 | Acat2阻害活性を示す代謝酵素に安定なピリピロペン誘導体 |
US9187492B2 (en) | 2010-03-31 | 2015-11-17 | School Juridical Person Kitasato Institute | Pyripyropene derivative having ACAT2 inhibiting activity and stable to metabolizing enzymes |
WO2011148886A1 (ja) | 2010-05-24 | 2011-12-01 | Meiji Seikaファルマ株式会社 | 有害生物防除剤 |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2014144922A (ja) * | 2013-01-28 | 2014-08-14 | Kitasato Institute | Acat2阻害活性を示すピリピロペンa構造簡略型誘導体 |
US9856478B2 (en) | 2013-10-30 | 2018-01-02 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
WO2015198966A1 (ja) * | 2014-06-24 | 2015-12-30 | 学校法人北里研究所 | コレステロールアシル転移酵素アイソザイム2(acat2)阻害活性を有する新規医薬化合物 |
JP2016008191A (ja) * | 2014-06-24 | 2016-01-18 | 学校法人北里研究所 | コレステロールアシル転移酵素アイソザイム2(acat2)阻害活性を有する新規医薬化合物 |
US9896456B2 (en) | 2014-06-24 | 2018-02-20 | School Juridical Person Kitasato Institute | Pharmaceutical compound having inhibitory activity against cholesterol acyltransferase isozyme 2 (ACAT2) |
WO2020063663A1 (zh) * | 2018-09-27 | 2020-04-02 | 中国科学院上海药物研究所 | 一类三环类似物、其制备方法和用途 |
CN110950881A (zh) * | 2018-09-27 | 2020-04-03 | 中国科学院上海药物研究所 | 一类三环类似物、其制备方法和用途 |
JPWO2021153570A1 (ja) * | 2020-01-27 | 2021-08-05 | ||
WO2021153570A1 (ja) * | 2020-01-27 | 2021-08-05 | 学校法人北里研究所 | プロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害剤及びその医薬用途 |
JP7430869B2 (ja) | 2020-01-27 | 2024-02-14 | 学校法人北里研究所 | プロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害剤及びその医薬用途 |
Also Published As
Publication number | Publication date |
---|---|
EP2228376A1 (en) | 2010-09-15 |
EP2228376A4 (en) | 2011-10-19 |
CN101965352A (zh) | 2011-02-02 |
US20110184173A1 (en) | 2011-07-28 |
EP2228376B1 (en) | 2015-06-03 |
BRPI0821921A2 (pt) | 2015-06-16 |
JPWO2009081957A1 (ja) | 2011-05-06 |
US8519128B2 (en) | 2013-08-27 |
JP5479110B2 (ja) | 2014-04-23 |
CA2710791A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009081957A1 (ja) | Acat 2 阻害活性を有するピリピロペン誘導体 | |
US5698527A (en) | Steroidal glycosides as antihyperlipidemic agents | |
KR20010033538A (ko) | ω-시클로알킬-프로스타글란딘 E2 유도체 | |
CN103539769B (zh) | 用作激酶抑制剂和hsp90抑制剂的大环化合物 | |
US5294724A (en) | 4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters and a process for their preparation | |
EP1612208B1 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
KR20120038986A (ko) | 이환식 화합물 및 이의 의약 용도 | |
WO1997035565A1 (fr) | Derives de cetone et usage medicinal | |
WO1999051587A1 (fr) | Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif | |
WO1996020176A1 (fr) | Derives d'huperzine a, leur preparation et leur emploi | |
EP2669280B1 (en) | Bicyclic compound and use thereof for medical purposes | |
CA2768814A1 (en) | Indole derivative or pharmaceutically acceptable salt thereof | |
JP5554330B2 (ja) | Acat2阻害活性を示す水酸基含有ピリピロペン誘導体 | |
JP5592482B2 (ja) | Acat2阻害活性を示す代謝酵素に安定なピリピロペン誘導体 | |
WO2007018193A1 (ja) | 新規セルコスポラミド誘導体 | |
WO2001062708A1 (fr) | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif | |
JP6773035B2 (ja) | Ep2アゴニスト活性を有する化合物 | |
CN110563631B (zh) | 一种抑制ido的化合物及其应用 | |
JP2014144922A (ja) | Acat2阻害活性を示すピリピロペンa構造簡略型誘導体 | |
AU2014226533A1 (en) | Isohexide monotriflates and process for synthesis thereof | |
ES2287310T3 (es) | Derivados de c-2' metilados de paclitaxel para usar como agentes antitumorales. | |
CA2192460A1 (en) | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants | |
EP1988087A1 (en) | Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of autoimmune diseases | |
JP4461772B2 (ja) | フェノール化合物からなる抗酸化剤 | |
AU726730B2 (en) | Delta 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880127445.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08864334 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009547119 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2710791 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008864334 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12810545 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0821921 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100624 |